A Fresh Coat: Innovation in Excipients - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A Fresh Coat: Innovation in Excipients
Sophisticated excipient development, especially for coatings, is staying on top of new challenges and meeting expanding industry needs.


Pharmaceutical Technology
Volume 32, Issue 11, pp. 46-56


(ALEX CAO, RAY MASSEY/GETTY IMAGES. ILLUSTRATION: M.MCEVOY)
In 1985, when Hubertus Folttmann, now head of global marketing excipients at BASF (Limbergerhof, Germany) started his career in the pharmaceutical industry, his company manufactured a drug product in three strengths, including an 80-mg tablet and a 120-mg tablet. To manufacture the 80-mg tablet, formulators simply replaced 40 mg of active ingredient in the 120 mg tablet with filler. "At that time, the world of pharma was okay," he says, "Health costs were not a topic, and manufacturing costs in the pharmaceutical industry were of minor importance."

Today, concerns about manufacturing costs and process times are at the forefront of fiscal budgets, and improving formulations is on every company's agenda. "Nowadays, smaller tablets are the advantage, and if you need less active ingredient, you are happy because then you need less excipients to formulate it." Not only do patients want to swallow smaller tablets, but if the capacity of process equipment determines the batch size, then there are more smaller tablets in a batch, which means less batch documentation, smaller packaging, less volume for transportation, and so forth. "Nowadays, these issues count," says Folttmann. "Excipients that perform their functions at lower concentration so that less material needs to be handled have a good chance of success in the marketplace."

Functionality and QbD

The US Food and Drug Administration's quality-by-design (QbD) initiative has changed the way excipient suppliers develop, characterize, and manufacture their materials. "We have seen some benefits of implementing QbD into the pharmaceutical manufacturing process, including a reduction in approval delays, a more streamlined approval process and an easier course for implementing postapproval changes," says Nandu Deorkar, director of research and development, laboratory and pharmaceutical products at Mallinckrodt Baker (Phillipsburg, NJ). "However, the concept of QbD can present implementation opportunities and challenges to both raw-material (excipient) suppliers and pharmaceutical manufacturers. As a part of the QbD system, raw-material characteristics and their variability on the process and product quality or performance should be studied and documented. As such, raw materials must be well-characterized and developed using QbD principles to reduce variability"


(IMAGES ARE COURTESY OF BASF.)
QbD principles also can facilitate the evaluation of excipient functionality performance and its correlation with physical and chemical properties. Better understanding of excipient properties related to intended uses can help design better dosage forms. "That is where we are getting involved now," says Dave Schoneker, director of global regulatory affairs at Colorcon (West Point, PA), "to build quality into the design from the beginning in terms of what customers want to achieve to make it a better product in the marketplace. In the past there has been a limited number of people within some pharmaceutical companies who could to do that." The company has built a computer-aided design program to help pharmaceutical clients virtually design their dosage forms, including size, shape, and color and produce physical models before producing placebo-type coated tablets. The modeling tool allows manufacturers to get a firm grasp of the tablet designs they want to take forward in development.

Engineering and coprocessing are additional sophisticated tools that can help excipient suppliers enhance their materials to the high-quality level demanded by drug makers. "QbD initiatives require well-characterized and highly functional excipients to enable their implementation by drug formulators," says Deorkar. "Excipient technology development is centered on particle engineering and new chemical entities." For example, Mallinckrodt Baker recently developed "PanExcea" performance excipients, spherical homogeneous particles for immediate-release oral dosage forms and orally disintegrating tablet forms, using a proprietary particle engineering technology. This technology enables the precise tailoring of physical attributes such as particle size, distribution, porosity, and density in homogeneous particles containing multiple components, without changing the chemistry. "This reduces unfavorable attributes, while enhancing the functional characteristics of individual components through synergistic effects," says Deorkar.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here